[1] HIRATA Y, MURAI N, YANAIHARA N, et al. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma[J]. BMC Cancer, 2014, 14(1): 799. DOI: 10.1186/1471-2407-14-799. [2] JÖNSSON J M, SKOVBJERG ARILDEN N, MALANEDR S, et al.Sex steroid hormone receptor expression affects ovarian cancer survival[J]. Transl Oncol, 2015, 8(5): 424-433. DOI: 10.1016/j.tranon.2015.09.002. [3] CHUNG Y W, BAE H S, SONG J Y, et al. Detection of microRNA s novel biomarkers of epithelial ovarian cancer from the serum of varian cancer patient[J]. Int J Gynecol Cancer, 2013, 23(4): 673-679. DOI: 10.1097/IGC.0b013e31828c166d. [4] AMERES S L, ZAMORE P D. Diversifying microRNA sequence and function[J]. Nat Rev Mol Cell Biol, 2013, 14(8): 475-488. DOI: 10.1038/nrm3611. [5] CATALANOTTO C, COGONI C, ZARDO G. MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions[J]. Int J Mol Sci, 2016, 17(10): E1712. DOI: 10.3390/ijms17101712. [6] DU X, LIU B, LUAN X, et al. miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy[J]. Exp Ther Med, 2018, 15(1): 599-605. DOI: 10.3892/etm.2017.5354. [7] LIU Y, YANG Z, DU F, et al. Molecular mechanisms of pathogenesis in hepatocellular carcinoma revealed by RNAsequencing[J]. 2017, 16(5): 6674-6682. DOI: 10.3892/mmr.2017.7457. [8] SONG M S, ROSSI J J. The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30[J]. Front Genet, 2014, 4: 301. DOI: 10.3389/fgene.2013.00301. [9] WANG X, QIU H, TANG R, et al. miR-30a inhibits epithelialmesenchymal transition and metastasis in triplenegative breast cancer by targeting ROR1[J]. Oncol Rep, 2018, 39(6): 2635-2643. DOI: 10.3892/or.2018.6379. [10] DI GENNARO A, DAMIANO V, BRISOTTO G, et al. A p53/miR-30a/ZEB2 axis controls triple negative breastanceraggressiveness[J]. Cell Death Differ, 2018, 25(12): 2165-2180. DOI: 10.1038/s41418-018-0103-x. [11] ZHANG H D, JIANG L H, SUN D W, et al. miR-30a inhibits the biological function of breast cancer cells by targeting Notchl[J]. Int J Mol Med, 2017, 40(4): 1235-1242. DOI: 10.3892/ijmm.2017.3084. [12] ZHANG L, ZHANG X W, LIU C H, et al. miRNA-30a functions as a tumor suppressor by downregulating cyclin E2 expression in castration-resistant prostate cancer[J]. Mol Med Rep,2016, 14(3): 2077-2084. DOI: 10.3892/mmr.2016.5469. [13] BOUFRAQECH M, NILUBOL N, ZHANG L, et al. miR30a inhibits LOX expression and anaplastic thyroid cancer progression[J]. Cancer Res, 2015, 75(2): 367-377. DOI: 10.1158/0008-5472.CAN-14-2304. [14] TSUKAMOTO O, MIURA K, MISHIMA H, et al. Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma[J]. Gynecol Oncol, 2014, 132(3): 715-721. DOI: 10.1016/j.ygyno.2014.01.029. [15] LIU J, WU X H, LIU H M, et al. Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines[J]. Oncology Letters, 2016, 12(3): 2065-2070. DOI: 10.3892/ol.2016.4831. |